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The discovery of lipid and glycolipid antigen 
recognition by CD1-restricted T cells defi  ned 
a new paradigm for immune recognition and 
host responses to infection. This is based on the 
fact that certain cellular and bacterial lipids, 
which bind to CD1 proteins, are able to acti-
vate T lymphocytes (1). It was also shown that 
CD1-restricted T cells have an infl  uence on 
the outcome of infections caused by viruses, 
protozoa, and fungi through the recognition of 
a great variety of lipids (1, 2). CD1 mole-
cules are divided into two groups: group 1 
contains CD1a, b, and c and group 2 contains 
CD1d (3). Group 1 CD1s mediate specifi  c 
T cell recognition of mycobacterial lipids (1), 
whereas CD1d is indispensable for the acti-
vation of iNKT cells, a conserved subpopula-
tion of NKT cell, characterized by a canonical 
Vα24/Jα18 TCR α-chain rearrangement and 
the preferential usage of Vβ11-chain giving rise 
to a semiinvariant T cell receptor (4). This cell 
type (iNKT) has been proposed to act as a gate-
keeper during the earliest stages of the innate 
immune response controlling DC diff  erentia-
tion, NK cell activation, and MHC-restricted 
T cell polarization (2).
DCs serve as regulators of immune responses 
and are considered the most effi   cient   professional 
APCs with the unique capability to activate 
  naive T cells (5). CD1 molecules are diff  erentially 
expressed by various DC subsets; however, the 
transcription factors or signals that regulate the 
diff  erentiation of these   functionally heteroge-
neous DC types are poorly defi  ned. Recently, 
we reported that the activation of PPARγ, 
a lipid-activated transcription factor, modulates 
the phenotype and function of DCs. PPARγ 
ligand–treated cells acquire higher phagocytic 
activity, express more CD1d, and display an 
enhanced capacity to activate iNKT cells than 
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Dendritic cells (DCs) expressing CD1d, a molecule responsible for lipid antigen presentation, 
are capable of enhancing natural killer T (iNKT) cell proliferation. The signals controlling 
CD1 expression and lipid antigen presentation are poorly defi  ned. We have shown previ-
ously that stimulation of the lipid-activated transcription factor, peroxisome proliferator-
activated receptor (PPAR)𝗄, indirectly regulates CD1d expression. Here we demonstrate 
that PPAR𝗄, turns on retinoic acid synthesis by inducing the expression of retinol and 
retinal metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydro-
genase type 2 (RALDH2). PPAR𝗄-regulated expression of these enzymes leads to an increase 
in the intracellular generation of all-trans retinoic acid (ATRA) from retinol. ATRA regu-
lates gene expression via the activation of the retinoic acid receptor (RAR)𝗂 in human DCs, 
and RAR𝗂 acutely regulates CD1d expression. The retinoic acid–induced elevated expression 
of CD1d is coupled to enhanced iNKT cell activation. Furthermore, in vivo relevant lipids 
such as oxidized low-density lipoprotein can also elicit retinoid signaling leading to CD1d 
up-regulation. These data show that regulation of retinoid metabolism and signaling is part 
of the PPAR𝗄-controlled transcriptional events in DCs. The uncovered mechanisms allow 
the DCs to respond to altered lipid homeostasis by changing CD1 gene expression.
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untreated cells (6). However, the regulation of CD1d by 
PPARγ appears to be indirect, because it takes at least 24 h 
to develop.
In search of downstream mechanisms, we found and 
documented here that the key enzymes involved in retinoid 
  metabolism are regulated by PPARγ in developing DCs 
  leading to all-trans retinoic acid (ATRA) production. ATRA 
is a   ligand for retinoic acid receptors (RARs) and is generated 
from retinol, a derivative of vitamin A. Retinol is metabo-
lized intracellularly by alcohol dehydrogenase (ADH) and/or 
short-chain dehydrogenase/reductases (SDR) to retinal, and 
subsequently retinal is oxidized by retinal dehydrogenases to 
retinoid acids (7, 8). Retinoids have been shown to modulate 
the immune response by acting on multiple cell types, but the 
mechanism of their action is still largely elusive. Retinoids are 
able to modify DC diff  erentiation, they promote apoptosis 
of DCs by an RARα-dependent pathway, and they enhance 
the maturation of DCs via a retinoid X receptor (RXR)-de-
pendent and an RAR-independent mechanism (9). A subtype 
of gut DCs can produce ATRA and regulates T cell homing 
(10). Here we describe a mechanism that utilizes PPARγ and 
RAR signaling pathways in human monocyte-derived DCs 
to control CD1d expression and iNKT activation in response 
to lipids.
RESULTS
Activation of PPAR𝗄 induces the expression of genes 
involved in retinoic acid biosynthesis
We have characterized the gene expression profi  le of PPARγ-
activated DCs using Aff  ymetrix GeneChips looking for PPARγ-
regulated metabolic and signaling pathways. Our global analyses 
revealed that PPARγ ligand modulates the expression of genes, 
which participate in lipid metabolism (fatty acid–binding protein 
[FABP]4, ADRP, LXRα) and lipid antigen presentation (CD1a, 
CD1d) in monocyte-derived DCs (6). Unexpectedly, we 
  observed that several genes involved in all-trans retinoic acid 
(ATRA) biosynthesis (Fig. 1 A) were also up-regulated by 
treatment of DCs with rosiglitazone (RSG), a synthetic PPARγ 
activator (Fig. 1 B). All of the identifi  ed retinol dehydrogenases, 
regulated by RSG treatment, are members of the SDR 
protein family. Several of them catalyze only the reduction 
of retinal, i.e., DHRS3 (11), whereas DHRS9 and retinol 
Figure 1.  Activation of PPAR𝗄 induces the expression of RDH10 
and RALDH2. (A) The retinoic acid biosynthesis pathway. (B) Expression 
profi  le of genes involved in retinoid metabolism in control or 2.5 μM 
rosiglitazone (RSG)-treated DCs. mRNA levels were determined by 
  Affymetrix GeneChips (Hu133 2.0 Plus), and expression was normalized to 
control cells. Heatmap shows expression levels; control levels are shown 
in yellow. RNAs were obtained from three donors. Transcript level of 
DHRS9 and RDH10 (C and D, respectively) was determined from control 
DCs or cells treated with 2.5 μM RSG by RT-Q-PCR. Samples were 
  obtained from three donors. Cells were harvested at the indicated time 
points (5 d or 24 h). (E) The mRNA level of RALDH2 was determined from 
monocytes (MC), control DCs, or cells treated with 2.5 μM RSG. Samples 
were obtained from three donors. (F) Protein expression of RALDH and 
RDH10 was determined from monocytes (MC), DCs, or cells treated 
with 2.5 μM RSG by IHC using pelleted cells as described in Materials 
and methods.JEM VOL. 203, October 2, 2006  2353
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dehydrogenase (RDH)10 are able to catalyze retinol oxida-
tion (12, 13) and thus may participate in the conversion of 
retinol to retinal (Fig. 1 A). The conversion of retinal to 
ATRA can be catalyzed by retinaldehyde dehydrogenase type 
2 (RALDH2), which also appeared to be regulated by PPARγ. 
These fi  ndings prompted us to investigate the relationship of 
PPARγ, retinoid metabolism, and retinoid signaling in mono-
cyte-derived DCs. First, we validated the enhanced gene 
  expression of retinol dehydrogenases by real-time quantitative 
PCR (RT-Q-PCR). Elevated levels of mRNA expression of 
DHRS9 and RDH10 were detected in RSG-treated DCs 
  after 5 d of diff  erentiation (Fig. 1, C and D). To further charac-
terize the onset of enzyme expression, we measured mRNA 
levels at earlier time-points. We reasoned that for a certain 
enzymatic reaction to contribute to DC diff  erentiation and/
or subtype specifi  cation it must be induced early during 
  diff  erentiation. Interestingly, only RDH10 was induced as 
early as 24 h (Fig. 1 D), suggesting that the PPARγ-regulated 
component of retinol oxidation might be RDH10. We also 
looked at the expression of the protein product of this gene 
and found an elevated level of RDH10 enzyme detected by 
immunohistochemistry (IHC) (Fig. 1 F). These results sug-
gested that PPARγ-activated cells are likely to acquire an in-
creased retinol to retinal conversion capacity. Our RT-Q-PCR 
data also revealed that RALDH2 (also known as ALDH1A2), 
the enzyme responsible for converting retinal to retinoic acid, 
was up-regulated upon PPARγ activation (Fig. 1 E). This 
  eff  ect was confi  rmed by IHC, which showed elevated protein 
expression of RALDH (Fig. 1 F)   using an anti-RALDH anti-
body, which can detect RALDH1 or RALDH2. It should be 
noted that the mRNA expression of RALDH1 was very low 
in monocyte-derived DCs   (unpublished data), suggesting that 
the detected signal is from RALDH2. Collectively, our results 
indicated that some key proteins, responsible for bioactive 
retinoid synthesis, are coordinately up-regulated in PPARγ-
instructed DCs.
PPAR𝗄 instructs DCs to produce ATRA
To obtain direct evidence that PPARγ ligand–treated DCs 
could generate retinoids we determined the intracellular 
ATRA concentrations by using a sensitive and specifi  c liquid 
chromatography–mass spectrometry (LC-MS) method (14). 
Untreated DCs produced very low levels of ATRA, but an 
elevated amount of ATRA was detected in RSG-treated 
DCs (Fig. 2 A). This accumulation appeared to be PPARγ 
dependent, because a PPARγ antagonist (GW9662) blocked 
it. The estimated ATRA concentration (0.8–1.2 ng/g cell 
pellet, equivalent to 2–5 nM) was well within the range to 
activate RARs (Fig. 2 B). The concentration of all-trans reti-
nol, the precursor of ATRA, was also determined in the cells, 
and no diff  erence was detected between treated and control 
samples (20–30 ng/g cell pellet). In addition, a similar retinol 
Figure 2.  PPAR𝗄-activated DCs produce ATRA. (A) Control (DC), 
RSG-treated (2.5 μM), or RSG plus GW9662–treated (5 μM) cells were 
cultured for 5 d and pooled from three donors (50–100 mg cell pellet). 
Concentrations of ATRA were determined with the LC-MS method. The 
ATRA peak is marked by an arrow. (B) Quantitative determination of ATRA 
from DCs and RSG-treated DCs. Data were obtained from four indepen-
dent experiments ± SD. (C) Expression pattern of RARα, RARγ, RXRα, 
and RXRβ in monocyte-derived DCs. Transcript levels were determined in 
DCs at the indicated time-points by real-time RT-Q-PCR using TLDA as-
says (Applied Biosystems). (D) Western blot analysis of RARα and RXRα 
protein expression in DCs. The identity of the 50-kD bands was confi  rmed 
by comigration with a band in the cell extract (2 μg) of RARα- or RXRα-
transduced 293T cells. Samples were obtained from two donors. GAPDH 
was used as a loading control. (E) TGM2 is up-regulated by RARα agonist. 
Cells were treated with 100 nM AM580 (AM), 100 nM CD437, or 100 nM 
ATRA. Transcript levels were determined by RT-Q-PCR.2354  PPARγ CONTROLS CD1D EXPRESSION VIA RETINOID SIGNALING | Szatmari et al.
concentration was detected in the culture medium (unpub-
lished data). These data strongly suggested that activation of 
PPARγ leads to ATRA production and potentially to reti-
noid-regulated gene expression. In other words, it appeared 
likely that part of the PPARγ-induced changes in gene ex-
pression are indeed retinoid mediated. Next, we embarked 
on evaluating this scenario. The eff  ects of retinoids on gene 
expression are mediated by nuclear receptors (RARs α, β, 
and γ and RXRs α, β, and γ) (15). We assessed the transcript 
levels of these receptors in diff  erentiated DCs. We observed 
that RARα and RXRα were highly expressed, tested both 
at mRNA (Fig. 2 C) and protein levels (Fig. 2 D), whereas 
RXRβ and RARγ were barely detectable. We failed to de-
tect RARβ or RXRγ (unpublished data). These results indi-
cated that the RARα–RXRα heterodimer is likely to be the 
dominant retinoid receptor in developing DCs. To assess the 
function of these receptors we monitored the mRNA level 
of tissue transglutaminase (TGM)2, a well-established retinoid 
receptor target gene (16). We examined the eff  ects of reti-
noids in developing DCs by using synthetic and natural RAR 
agonists. ATRA, a natural ligand of RARs, and AM580, an 
RARα selective synthetic ligand, strongly induced the ex-
pression of TGM2, but the RARγ-specifi  c agonist (CD437) 
did not (Fig. 2 E). These fi  ndings implied that PPARγ-
treated DCs produce ATRA, and endogenous accumulation 
of this compound might trigger the retinoid response by the 
activation of the RARα nuclear hormone receptor.
Part of PPAR𝗄-regulated gene expression is a result 
of retinoid signaling in DCs
Our data provided several hints that activation of PPARγ 
  induces a retinoid response in human DCs. (a) Key proteins 
responsible for bioactive retinoid synthesis are up-regulated 
in PPARγ-instructed DCs. (b) PPARγ ligand–treated cells 
produce a detectable amount of ATRA. (c) Retinoid tar-
get genes, i.e., TGM2 and DHRS3 (17), were induced by 
PPARγ ligand (Fig. 1 B and unpublished data). To assess 
the contribution of retinoid signaling to the PPARγ response 
we decided to use a combination of pharmacological activa-
tors and inhibitors of these pathways along with an unbiased 
approach—global gene expression profi  ling. Cells were treated 
with the synthetic PPARγ ligand RSG, or with RSG along 
with the RARα antagonist (AGN193109), to block RARα-
mediated gene expression, or the RARα-specifi  c  agonists 
(AM580) alone. This design allows one to determine if retinoid 
signaling is a downstream event of PPARγ activation and 
what portion of PPARγ-regulated genes is regulated via 
  induced retinoid signaling. We found that 553 probe sets were 
signifi  cantly changed in a PPARγ-dependent manner (micro-
array analyses are described in the supplemental Materials and 
methods, available at http://www.jem.org/cgi/content/full/
jem.20060141/DC1). Datasets are available in the public Gene 
Expression Omnibus database (accession no. GSE5679). We 
performed K-means clustering to fi  nd characteristic gene 
  expression patterns. Six clusters were generated by this   analysis 
Figure 3.  Comparative gene expression profi  le of PPAR𝗄 
and RAR𝗂 ligand–treated DCs. (A) Microarray data were obtained from 
vehicle (DC) or ligand treated DCs: 2.5 μM RSG, 1 μM AGN193109 (AGN), 
100 nM AM580 (AM). Data analyses are described in detailed in the sup-
plemental Materials and methods. Gene expression was normalized to 
control DCs. Heatmap shows gene expression level. (B) Transcript levels of 
FABP4, RDH10, TGM2, CD1d, and CD1a were determined with RT-Q-PCR. 
Cells were treated as described above.JEM VOL. 203, October 2, 2006  2355
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(Fig. 3 A); cluster 1 contains probe sets, which were exclusively 
PPARγ ligand regulated. The RARα  antagonist did not 
  decrease and the RARα agonist did not increase the expres-
sion of these genes. In this cluster several established PPARγ-
responsive genes such as FABP4 and ADRP were found; in 
addition, the newly identifi  ed target gene RDH10 was also 
in this group. Our quantitative PCR analysis confi  rmed that 
FABP4 and RDH10 were regulated only by PPARγ agonist 
(Fig. 3 B). In cluster 3 (see gene list in Table S1, available 
at http://www.jem.org/cgi/content/full/jem.20060141/
DC1) gene expression was regulated by both ligands, and 
the RARα antagonist abolished the eff  ect of the PPARγ 
  ligand. As expected, TGM2 was in this cluster, but surpris-
ingly the previously characterized PPARγ-regulated gene, 
CD1d (6), also fell into this category. These genes appeared 
to be regulated indirectly by PPARγ via the activation of 
retinoid signaling. RT-Q-PCR validation of these fi  ndings 
indicated that the gene expression pattern of CD1d was very 
similar to that of TGM2 (Fig. 3 B), suggesting that CD1d is 
indeed regulated in an RARα-dependent manner. We also 
  identifi  ed several genes, which were induced independently 
by either of the two types of ligands (cluster 2). Interestingly, 
a p450 enzyme, CYP27, was also in this group. We have 
previously analyzed the promoter region of this gene (18) and 
have now confi  rmed that it is regulated by either PPARγ or 
RAR. We obtained a similar set of   expression patterns when 
we analyzed the down-regulated genes. Most   prominently, 
cluster 6 contains probe sets of genes down-regulated by 
PPARγ ligand. This eff  ect is abolished in the presence of 
the RARα antagonist (see gene list in Table S2, available at 
http://www.jem.org/cgi/content/full/jem.20060141/DC1). 
CD1a belong to this group, and the expression of CD1a 
was confi  rmed using RT-Q-PCR. If taken together, our global 
gene expression profi   ling data implies that  30% of all 
PPARγ ligand–responsive genes are regulated via the induc-
tion of retinoid signaling. Thus, PPARγ-regulated retinoid 
production signifi  cantly contributes to both induced and in-
hibited gene expression in DCs.
PPAR𝗄-mediated CD1d induction requires induced 
retinoic acid synthesis
The fi   nding that RARα antagonist abolished PPARγ 
ligand–induced CD1d expression suggested that the link be-
tween PPARγ and retinoid signaling is likely to be at the 
level of induced retinoid production. If this argument is cor-
rect, increased intracellular ATRA levels should correlate 
with the expression of CD1d in PPARγ ligand–treated DCs. 
We have performed time course experiments to address this. 
As shown in Fig. 4 A, the time course of intracellular ATRA 
production matches the induction of CD1d, providing fur-
ther evidence that there is a causative relationship between 
retinoic acid production and CD1d induction. To gain fur-
ther mechanistic insights, we used pharmacological means to 
probe the contribution of enzymatic steps in the regulation of 
Figure 4.  Inhibition of retinoid synthesis blocks PPAR-dependent 
CD1d and TGM2 induction. (A) Quantitative determination of ATRA 
concentration from RSG-treated DCs. Cells were treated with 2.5 μM RSG 
harvested at the indicated time points; cell pellets from eight donors 
(top). Determination of CD1d transcript level from RSG-treated DCs. Cells 
were treated as described above; mRNA level was determined by RT-Q-PCR 
(bottom). (B) ATRA biosynthesis and degradation pathway. Oxo/OH ATRA, 
oxo/hydroxi ATRA; CYP26, cytochrome p450 retinoic acid 4-hydroxilase; 
R115, R115866. (C) Transcript levels of TGM2, CD1d, and FABP4 were 
  determined from DCs treated with various ligands: 2.5 μM RSG, 
10 μM 4-diethyl amino-benzaldehyde (DEAB), 1 μM R115866 (abbreviated 
as R115), and 100 nM AM580 (AM) ***P < 0.001.2356  PPARγ CONTROLS CD1D EXPRESSION VIA RETINOID SIGNALING | Szatmari et al.
gene expression. We used inhibitors of the enzymatic steps 
involved in retinoic acid synthesis. Retinal is converted to 
ATRA by aldehyde dehydrogenases (Fig. 4 B). This step can 
be blocked by 4-diethyl amino-benzaldehyde (DEAB) (19), 
an inhibitor of RALDHs. ATRA is inactivated by CYP26, 
a p450 enzyme. This step can be inhibited by R115866, a spe-
cifi  c CYP26 inhibitor (20). We used these inhibitors in com-
bination with activators of PPARγ or RARα. As a readout 
of activation, we measured the expression of the PPARγ tar-
get gene FABP4 and the RARα-regulated genes TGM2 and 
CD1d. We found that PPARγ ligand–mediated induction 
of CD1d and TGM2 was completely abolished by RALDH 
inhibitor (DEAB) treatment. Conversely, administration of 
R115866 (abbreviated as R115) led to an enhanced expres-
sion of CD1d (Fig. 4 C). At the same time DEAB did not 
abolish the induction of FABP4, indicating that this com-
pound is not a general inhibitor of PPARγ-induced gene ex-
pression. We also examined the eff  ect of RALDH inhibitor 
on CD1d and TGM2 expression upon retinoid treatment. 
When cells were cotreated with the synthetic RARα agonist 
AM580, DEAB had no eff  ect on the induction (Fig. 4 C). 
These data provided further support for the argument that 
endogenously generated ATRA is likely to be responsible for 
TGM2 and CD1d induction by PPARγ ligands.
CD1d is acutely up-regulated by the activation 
of the RAR𝗂 receptor
One of the unanticipated fi  ndings of our global gene expres-
sion analyses was that both CD1d and CD1a were regulated 
by PPARγ in an RAR-dependent manner. Next, we wanted 
to gain more insight into how retinoic acid and its receptor 
(RARα) regulated CD1d gene expression. First, we com-
pared the time courses of CD1d induction by PPARγ activa-
tors and retinoids. We reasoned that if retinoid-induced 
CD1d expression is downstream of PPARγ, then there must 
be a shift between the two time courses. It appears to be the 
case, because activation of RARα induced expression of 
CD1d already after 1 h, suggesting the involvement of a di-
rect transcriptional event (Fig. 5 A), whereas PPARγ ligand 
administration did not up-regulate the expression of CD1d 
within this time interval as we have previously reported (6). 
This expression pattern is consistent with an indirect mecha-
nism triggered by PPARγ activation. The analysis of CD1d 
expression, however, is complicated by the fact that freshly 
isolated monocytes also express large amounts of CD1d; thus, 
it is diffi   cult to determine whether retinoids elicit a net 
  induction or block the down-regulation of CD1d. To 
  circumvent this issue we added the activators after 12 h of 
DC diff  erentiation (when CD1d expression is already low). 
Signifi  cantly, we detected an early and robust induction of 
CD1d by retinoids (Fig. 5 B). In contrast, to this prompt ef-
fect, PPARγ ligand failed to activate this gene after 2 h. To 
see if retinoids have similar eff  ects in cell types other than 
monocyte-derived DCs we extended our studies into other 
DC models. We characterized the expression of CD1d in 
blood DCs. We isolated CD1c+ myeloid DCs from mono-
cyte-depleted PBMCs (6). Cultured blood DCs express low 
amount of CD1d, but CD1d was highly up-regulated upon 
retinoid (AM580) treatment (Fig. 5 C). PPARγ activator was 
also eff  ective albeit much less potent. Based on the evidence 
presented here, we propose that the eff  ect of retinoids on 
CD1d gene expression is likely to be a “proximal” direct 
transcriptional event and the PPARγ-dependent regulation 
of CD1d is indirectly mediated through the activation of 
  retinoid signaling.
Retinoid-treated DCs have an improved lipid 
presentation capacity
We and others have recently shown that the expression of the 
CD1 gene family is coordinately regulated by PPARγ activa-
tors. PPARγ ligand–treated DCs express a reduced level 
of CD1a, whereas the level of CD1d is increased upon ligand 
treatment (6, 21). Our results presented here argued strong-
ly for the possibility that some of the regulation on CD1 
  expression is mediated by retinoid signaling. Therefore, we 
decided to compare the eff  ects of retinoids and PPARγ 
  activators on the expression of cell surface molecules of 
DCs. We sought to characterize the retinoid-regulated events 
and compare those to PPARγ-regulated processes. First, we 
looked at the cell surface expression of CD1a and CD1d. 
Figure 5.  CD1d is rapidly and robustly induced by retinoids, and CD1d 
is also up-regulated in blood DCs by retinoid treatment. (A) Time course 
of regulated CD1d expression. Cells were treated with 1 μM RSG or 100 nM 
AM580, harvested at the indicated time points, and mRNA expression was 
determined by RT-Q-PCR. (B) Determination of CD1d mRNA level upon acute 
retinoid treatment. Monocytes were cultured for 12 h, thereafter treated with 
100 nM ATRA or 1 μM RSG, and harvested after 2 h. (C) CD1d transcript level 
was determined from blood-derived DCs (bDCs) cultured for 2 d. Cells were 
treated with 1 μM RSG or 100 nM AM580 (AM); transcript levels were deter-
mined by RT-Q-PCR. Samples were obtained from two donors.JEM VOL. 203, October 2, 2006  2357
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Consistent with the mRNA expression pattern membrane, 
CD1d was up-regulated, whereas CD1a was down-modu-
lated by both RARα and PPARγ ligands (Fig. 6 A). Impor-
tantly and also consistent with the mRNA expression pattern, 
we observed that RSG-elicited induction of CD1d was abol-
ished by a RALDH inhibitor (DEAB) (Fig. 6 A). Next, we 
looked at the functional consequences of retinoid-regulated 
gene expression. CD1d can present lipid antigens to a spe-
cifi  c T cell subtype, iNKT cells, which have the potential to 
regulate both infl  ammatory and antiinfl  ammatory responses 
through the rapid secretion of cytokines (4). We assessed the 
ability of DCs to induce iNKT cell proliferation in autolo-
gous mixed leukocyte reaction (MLR) cultures. DCs were 
loaded with a synthetic CD1d ligand (α-GalCer) (22) for 24 h 
followed by a co-culture with autologous PBMCs for 5 d. 
We found that either RARα or PPARγ activation leads to a 
DC subtype, which has an increased capacity to promote the 
expansion of iNKT cells (Fig. 6, B and C). In addition, we 
also loaded the cells with galactosyl(a1-2) galactosyl-ceramide 
(GGC), a lipid precursor of the α-GalCer antigen, which re-
quires delivery to the lysosomes where it is hydrolyzed and 
converted to the active glycolipid (α-GalCer) (23). PPARγ 
or RARα receptor agonist–treated DCs elicited an enhanced 
iNKT expansion when the cells were loaded with this pre-
cursor of α-GalCer (Fig. 6 D), indicating that activation of 
these pathways enhance the lipid antigen-presenting capacity 
independent of processing and endosomal loading. To pro-
vide further evidence that ligand-instructed DCs could acti-
vate iNKT cells we measured INFγ secretion of purifi  ed 
iNKT cells, activated by α-GalCer–loaded DCs, by ELISPOT 
analysis. We found that both RARα and PPARγ ligand–
treated DCs trigger an enhanced INFγ response of iNKT 
cells (Fig. 6 E). Our results demonstrated that both PPARγ- 
and RARα-specifi  c ligand–treated DCs express CD1d that is 
able to present α-GalCer for iNKT cells to elicit their activa-
tion. It should be noted that ligand-treated DCs without 
  exogenous glycolipid loading failed to elicit any iNKT cell 
expansion (Fig. 6, C and D).
Besides presentation of lipid antigens, DCs are highly ac-
tive in the presentation of processed peptides by MHC class I 
and/or class II proteins. The question remained whether ac-
tivation of either the PPARγ or the RARα pathways had an 
Figure 6.  Retinoid-treated DCs express CD1d and promote the ex-
pansion and activation of iNKT cells. (A) PPARγ and RARα ligand–treated 
cells express more CD1d and less CD1a compared to control cells. Cells were 
treated with various ligands: 2.5 μM RSG alone, or along with 10 μM DEAB, 
100 nM AM580 (AM), or 100 nM ATRA. Specifi  c mAb (solid line) versus iso-
type control (dotted line) is presented. (B) Ligand-treated (2.5 μM RSG or 
100 nM AM580) DCs were pulsed with 100 ng/ml α-GalCer for 24 h, and 
then DCs were washed and cocultured with autologous PBMCs for 5 d. Cells 
were stained by iNKT antibodies (anti–Vβ11-PE and anti–Vα24-FITC). (C and D) 
Cells were treated with the following ligands: 2.5 μM RSG, 100 nM AM580, 
or 100 nM ATRA, and cells were pulsed with 100 ng/ml α-GalCer (GC) or with 
100 ng/ml GGC for 24 h. The percentage of NKT was determined as described 
above. We performed a duplicate measurement (blue and red color). (E) De-
tection of iNKT activation by INFγ ELISPOT. α-GalCer–pulsed DCs were cocul-
tured with iNKT cells for 16 h in human INFγ ELISpot plates. Cells were 
treated with 2.5 μM RSG (DC RSG) or with 100 nM AM580 (DC AM).2358  PPARγ CONTROLS CD1D EXPRESSION VIA RETINOID SIGNALING | Szatmari et al.
eff  ect on MHC-mediated T cell activation. PPARγ ligand–
activated immature DCs exhibit an elevated expression of 
MHC class II molecules (21). We confi  rmed these results and 
extended them by phenotyping retinoid (ATRA or AM580)-
treated cells in combination with measuring MHC class I 
(HLA-ABC) membrane expression. Retinoid-treated cells 
showed a similar HLA-DR expression pattern to PPARγ-
activated cells. Both ligands stimulated the cell surface ex-
pression of HLA-DR, suggesting that these cells might have 
a generally enhanced capacity to present peptide antigens 
(Fig. S1 A, available at http://www.jem.org/cgi/content/
full/jem.20060141/DC1). In contrast to CD1s, the cell sur-
face expression of MHC II was highly up-regulated upon 
maturation/activation of DCs (24), and it was also suggested 
that retinoid-treated DCs had a mature/activated phenotype 
(9, 25). Consistent with this fi  nding we also found that in 
immature DCs the cell surface expression of HLA-DR was 
increased upon retinoid treatment, but the bona fi  de matura-
tion marker (CD83) was not detected (unpublished data). It 
is possible that enhanced HLA-DR expression is just a marker 
of the activation state of these cells, and its expression can be 
further elevated by proinfl  ammatory cytokines. Indeed, we 
found that mature DCs (MDCs) exhibited elevated expression 
of HLA-DR, which was not modifi  ed by retinoids (Fig. S1 B). 
We also investigated the cell surface expression of HLA-ABC 
and found that both immature and mature DCs express 
high levels of MHC class I molecules not modifi  ed by 
ligand treatment. To see if activation of RARα had any 
eff  ect on DC-mediated T cell activation we compared the 
intensity of MLR reactions induced by mature DCs  generated 
with or without RARα or PPARγ agonist. We failed to 
observe any change in the level of MHC-dependent T cell 
activation using control or ligand-treated MDCs in an alloge-
neic MLR test (Fig. S1 C). We concluded that activation 
of these nuclear receptors did not confer enhanced antigen-
presenting capacity per se, but the activated cells acquired 
a selectively enhanced NKT cell activating capacity caused 
by elevated levels of membrane CD1d accompanied by de-
creased CD1a expression.
Activation of retinoid signaling by natural PPAR𝗄 activators
Our studies uncovered an interrelated network of lipid sig-
naling processes regulating DC gene expression and function 
including lipid antigen presentation. An intriguing question 
remained, however, whether natural sources of PPARγ ac-
tivators such as oxidized low density lipoprotein (oxLDL) 
or other lipids (26) were able to elicit retinoid signaling 
in DCs, providing a biological context and signifi  cance for 
these mechanisms. To test this hypothesis diff  erentiating 
DCs were treated with oxLDL alone or in combination with 
RAR antagonist or RALDH inhibitor,  and the expression 
pattern of retinoid and PPARγ-regulated genes was mea-
sured. oxLDL treatment induced the expression of CD1d, 
TGM2, and FABP4 (Fig. 7 A). Treatment with the RAR 
antagonist and RALDH inhibitor blocked the up-regulation 
of TGM2 and CD1d, suggesting that retinoid signaling was 
Figure 7.  Natural PPAR𝗄 agonists confer retinoid response to hu-
man DCs. (A and B) Transcript levels of TGM2, CD1d, and FABP4 were 
determined by RT-Q-PCR after treatment with the following ligands: 
100 nM AM580 (AM), 2.5 μM RSG, 1 μM AGN193109 (AGN), 5 μM 
GW9662, 10 μM DEAB, or 20 μg/ml oxidized low density lipoprotein 
  (oxLDL). The indicated samples were cultured in human AB serum.JEM VOL. 203, October 2, 2006  2359
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involved, but it did not block the up-regulation of FABP4. 
It is important to note, however, that lipoproteins besides 
PPARγ activators might also contain retinyl-esters or other 
retinoid precursors (27, 28), and these compounds might 
participate in the activation of retinoid signaling indepen-
dent of the activation of the PPARγ receptor. To test this 
we also analyzed the retinoid content of oxLDL by LC-MS. 
Although we could detect various retinyl-esters, only trace 
amounts of retinol was found and no ATRA was detected 
in 100 mg of oxLDL. Our lipid analyses also indicated that 
several oxidized retinoid species were present (unpublished 
data). These data imply that oxLDL is likely to contain reti-
noic acid precursors that can be converted to ATRA inside 
cells and elicit retinoid signaling. The conversion of this 
(these) precursor(s) are also, at least in part, under the con-
trol of PPARγ. In addition, we have previously defi  ned a 
serum condition (human AB serum), which either contains 
and/or induces endogenous PPARγ ligands/activators (6). 
Next we tested if this source of PPARγ activators induced 
retinoid signaling. In DCs cultured in the presence of hu-
man AB serum an elevated level of FABP4, TGM2, and 
CD1d was detected (Fig. 7 B). The PPARγ-specifi  c antago-
nist (GW9662) effi   ciently decreased the transcript level of all 
of these genes. Importantly, administration of RAR antago-
nist or RALDH inhibitor (DEAB) diminished the expres-
sion of TGM2 and CD1d but not that of FABP4 (Fig. 7 B). 
These experiments collectively demonstrated that activation 
of PPARγ by biologically relevant normal or pathological 
serum lipids can also elicit a retinoid response, and it appears 
likely that in vivo these lipids might be relevant sources of 
CD1d regulation.
DISCUSSION
Lipid exposure to APCs, including DCs, has fundamental 
eff  ects on their diff  erentiation and immune function (2). 
The molecular, and in particular, the transcriptional mech-
anisms contributing to these changes are not well under-
stood. Here we describe a network of regulatory processes 
involving two lipid-activated transcription factors, PPARγ 
and RARα, controlling CD1 gene expression and lipid an-
tigen presentation in human developing DCs. Based on the 
data presented, the following model is emerging: if the lipid 
environment is permissive for PPARγ receptor activation 
(i.e., exposure to synthetic PPARγ ligands, oxidized LDL, 
or human serum), the expression of several genes (RDH10 
and  RALDH2), acting at subsequent stages of retinoid 
  metabolism, are induced. CD1d along with other retinoid 
targets gets induced and another set of genes including 
CD1a is down-modulated (Fig. 8), bringing about func-
tional changes in lipid antigen-presenting capacity of DCs 
and iNKT cell activation. The described pathway might be 
induced by activation of either one or both of the receptors 
allowing for graded and/or synergistic regulation. As a re-
sult, the gene expression pattern and the functions of DCs 
will be changed depending on the intracellular and extra-
cellular lipid environment.
Regulated production of all-trans retinoic acid in DCs
In vivo, endogenous retinol metabolism is a tightly controlled 
process (7, 8); however, it is largely unknown which type of 
immune cells are able to generate the active form of vitamin A. 
It was recently shown that murine intestine-associated DCs 
could produce retinoids, but DCs from other tissues failed 
to produce ATRA (10). In addition, several retinol/retinal 
metabolizing enzymes were detected in intestinal DCs. In our 
studies, we identifi  ed several genes participating in retinoid 
metabolism in human DCs, which had an   increased expres-
sion level in cells treated with PPARγ acti  vators. Time course 
experiments and receptor selective inhibitors helped to estab-
lish that PPARγ acted upstream of retinoid signaling. One 
of the regulated steps, RDH10 expression and activity, can 
  initiate ATRA production in a PPARγ-dependent manner. 
We also observed that the expression of RALDH2 was highly 
increased during DC development, and PPARγ ligand–
treated cells showed a further elevated level. Therefore, it 
is very likely that RALDH2 is required for the enhanced 
  production of ATRA. These data also suggest that retinoid 
production is not an inherent characteristic of DCs but an 
acquired/regulated one. Our data support a model for such 
controlled retinoid production and signaling in human DCs 
and suggests that ligand activation of PPARγ is acting as one 
of the regulators. In our case,  30% of the gene expression 
changes are caused by induced retinoid signaling. Besides 
CD1d, several other transcripts get up-regulated in this way 
(i.e., DHRS3, fi  bronectin, TGM2), suggesting that this reg-
ulatory mechanism can modulate other pathways that might 
have roles in DC function.
Biological roles for PPAR𝗄-controlled retinoid production
It is also conceivable that the produced lipid mediators such 
as retinoids are exported from the cells and modify the 
  function of exposed neighboring cells. DCs interact with 
almost all types of immune cells and are important regulators of 
both adaptive and innate immune responses while controlling 
  immunological tolerance. DCs collaborate also with epithelial 
cells, and much of their eff  ects are implemented at the interface 
Figure 8.  Regulation of gene expression, including CD1d expres-
sion, by the activation of nuclear hormone receptors in developing 
DCs. 1. ATRA or synthetic RARα agonist acutely induces CD1d expression. 
2. Generation of ATRA and enhanced retinoid signaling in PPARγ ligand–
treated DCs.2360  PPARγ CONTROLS CD1D EXPRESSION VIA RETINOID SIGNALING | Szatmari et al.
of DC and lymphocytes. Retinoids have been shown to have 
a profound eff  ect on T cell activation (29). One could specu-
late that locally generated ATRA by PPARγ-activated DCs, 
besides acting in DCs, if exported, might also infl  uence the 
functions of local cells, such as epithelial cells (30, 31), mono-
cytes, and B and T lymphocytes. It is also plausible that the 
small intestine is the place where intense lipid traffi   c occurs and 
PPARγ activators can be generated. We have preliminary data 
to suggest that some of the DCs of Peyer’s patches are PPARγ 
positive, and these cells also express RALDH and are likely 
to generate retinoids in a regulated manner. Remarkably, all 
the PPARγ positive cells coexpress TGM2, a bona fi  de reti-
noid target gene, strongly suggesting that these cells have active 
retinoid signaling and that PPARγ-positive DCs in Peyer’s 
patches is an in vivo identifi  able and thus relevant cell type 
(unpublished data).
The regulatory effects of exogenous lipids 
from physiological and pathological sources
Mediators (such as oxLDL, prostaglandins, and other serum 
lipids) of PPARγ activation might switch on this pathway 
leading to retinoid generation provided that precursors are 
also present. In fact, we observed that oxLDL promoted CD1d 
induction in human DCs via activation of retinoid signaling. 
It is very intriguing to speculate that turning on the lipid-
  presenting molecule CD1d and lipid antigen production and 
presentation might also be linked. It was recently shown that 
lipoproteins can promote the delivery of exogenous glycolipid 
antigens to the CD1d antigen–loading compartments in human 
DCs (23). It is possible that oxLDL also participates in this 
process; therefore, in addition to the induction of CD1d, 
  oxLDL might also modulate the uptake of glycolipid antigens 
in these cells. Interestingly and in agreement with this model, 
it was also shown that oxLDL in murine peritoneal macro-
phage elicits CD1d induction and that CD1d-dependent 
iNKT activation has a proatherogenic eff  ect (32, 33). These 
data are consistent with our previous results on PPARγ-
  mediated CD1d regulation and with the data presented here.
The transcriptional regulation of CD1d and CD1a appears 
to be coupled and inverse
We have shown previously that ligand activation of PPARγ 
induced CD1d and inhibited CD1a expression. Now by 
identifying the proximal mechanism we have found that 
  activation of the RAR has an eff  ect similar to that of PPARγ 
on CD1a and CD1d expression. These two molecules belong 
to group 1 (CD1a) and group 2 (CD1d) CD1 proteins. There 
are emerging lines of evidence to suggest that the timing of 
their expression, the mode of their regulation, and function 
may also be diff  erent. Group 1 CD1s are not expressed in 
monocytes and other myeloid precursors but are induced 
upon DC differentiation. It has also been suggested that 
  myeloid cells such as DCs express group 1 CD1 mRNA and 
proteins as a result of contact with pathogens such as myco-
bacteria, TLR agonists, or cytokines (34). In contrast to group I 
CD1 molecules, the expression of CD1d can be increased by 
  viruses and bacteria and by activators of PPARγ. It is also 
  intriguing that a single microbial stimulus (i.e., mycobacterial 
lipids) can oppositely regulate group 1 and group 2 CD1s (34). 
Our data presented here is very much in line with this 
  scenario and suggests that depending on the actual lipid envi-
ronment, the activation of either PPARγ and/or RAR 
would regulate CD1d and CD1a in opposite directions. This 
hypothesis is further supported by two additional notions. 
One is that CD1a and CD1d have distinct functions caused 
by dissociable and opposite regulation. The second is that 
certain lipids present in the immune milieu might contribute 
to changing CD1 expression to arm the cell with the needed 
CD1 species for presenting lipids the cell become exposed to 
because of the altered lipid environment (2). Our studies 
identifi  ed lipids such as oxLDL, normal human serum, and 
retinoids as lipid species regulating CD1 expression. Some of 
these contain  activators or precursors of activators for PPARγ, 
RAR, or both. The functional consequence of this is that the 
presence of PPARγ-activating lipids or retinoic acid would 
dictate CD1 expression during DC diff  erentiation, leading to 
a CD1d-positive and CD1a-negative potentially antiinfl  am-
matory cell, or the lack of these lipids and/or the presence 
of other lipids would promote the diff  erentiation of a CD1a-
positive and CD1d-negative cell responding to the attack of 
infectious agents (i.e., mycobacteria). Thus, the regulated pro-
duction of retinoic acid appears to be a key mediator of this 
process and a determinant of CD1 expression in developing 
DCs. This eff  ect appears to be specifi  c for modifying lipid 
antigen presentation capacity and has little or no infl  uence on 
MHC-mediated antigen presentation.
In summary, our fi  ndings provide molecular insights into 
the regulatory logic and the interrelatedness of lipid signaling 
(retinoid and fatty acid) and lipid antigen presentation. These 
pathways might also be amenable for therapeutic interven-
tion in infl  ammatory and immune diseases.
MATERIALS AND METHODS
Ligands. Cells were treated with the following ligands: AM580 (Biomol), 
rosiglitazone and GW9662, (Alexis Biochemicals), and AGN193109 (a gift 
from R.A.S. Chandraratna, Allergan Inc., Irvine CA). oxLDL was obtained 
from Intracel, R115866 was obtained from Janssen, DEAB was obtained 
from Fluka, and α-GalCer was obtained from Kirin Brewery Ltd. GGC was 
described previously (23).
Cell culture and ligand treatment. Monocytes (98% CD14+) were ob-
tained from Buff  y coats by Ficoll gradient centrifugation and magnetic cell 
separation using anti-CD14–conjugated microbeads (VarioMACS; Miltenyi 
Biotec). DCs were prepared as described previously (6) with minor modifi  -
cations. In brief, monocytes were resuspended into six-well culture dishes at 
a density of 1.5 × 106 cells/ml and cultured in RPMI 1640 (Sigma-Aldrich) 
supplemented with 10% FBS (Invitrogen) containing 800 U/ml GM-CSF 
(Peprotech) and 500 U/ml IL-4 (Peprotech). In some experiments, FBS was 
replaced with human AB serum (Sigma-Aldrich). Cells were cultured for 
5 or 6 d, and the IL-4 and GM-CSF addition was repeated at day 3. Ligands 
or vehicle control (50% DMSO/ethanol) were added to the cell culture 
starting from the fi  rst day or otherwise indicated. AGN193109 administra-
tion was always repeated at day 3. To obtain MDCs, DCs were treated with 
the following mix of cytokines for 24 h: 10 ng/ml TNF-α, 10 ng/ml IL-1β, 
1,000 U/ml IL-6 (Peprotech), and 1 μg/ml PGE2 (Sigma-Aldrich).JEM VOL. 203, October 2, 2006  2361
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Peripheral blood myeloid DCs were magnetically isolated with the 
CD1c (BDCA-1) Dendritic Cell Isolation kit (Miltenyi Biotec) from mono-
cyte-depleted PBMCs. Blood myeloid DCs (105 cells/ml) were cultured for 
2 d in RPMI 1640 supplemented with 10% FBS.
Immunohistochemistry. Monocytes, DCs, or RSG-treated DCs 
(6 × 106 cells/group) were pelleted and fi  xed in 4% paraformaldehyde 
(pH 7.3) for 24 h at 4°C. Cell blocks were then embedded in paraffi   n 
followed by serial sectionings (4 μm thick). After deparaffi   nization and 
dehydration, serial sections from each cell group, mounted on the same 
glass slides, were used for peroxidase-based indirect IHC. In brief, sec-
tions were treated with 3% H2O2 in methanol for 15 min at room tem-
perature to block the endogenous peroxidase. For antigen unmasking, 
sections were heated in antigen-retrieving citrate buff  er (pH 6.0; Dako) 
for 2 min at 120°C using a pressure cooker. IHC stainings were with the 
standard ABC technique using the primary antibody-specifi  c biotinylated 
secondary antibodies (Vectastain kits; Vector Laboratories). After block-
ing the nonspecifi  c binding sites, sections were incubated with the pri-
mary antibodies for 1 h at room temperature before using the biotinylated 
secondary antibodies. The peroxidase-mediated color development was 
set up for 5 min using the VIP substrate (Vector Laboratories). Finally, 
the sections were counterstained with methylgreen. The following anti-
bodies were applied: rabbit antibody to RDH10 (13) in a dilution of 
×1/75 and goat antibody to ALDH1A1 (RALDH1, ab9883; Abcam) 
in a dilution of ×1/75.
Western blot analysis. 20 μg protein whole cell extract was separated by 
electrophoresis in 12.5% polyacrylamide gel and then transferred to PVDF 
membrane (Bio-Rad Laboratories). Membranes were probed with anti-
RARα (2ZH1920L; Perseus Proteomics) or anti-RXRα (2ZK8508H; Per-
seus Proteomics) antibodies, and then the membranes were stripped and 
reprobed with anti-GAPDH (ab8245-100; Abcam) according to the manu-
facturer’s recommendations.
Mixed leukocyte reaction. MDCs were collected, extensively washed, 
and used as stimulator cells for allogeneic PBMCs (2 × 105 cells/well). Stim-
ulator cells were added in graded doses to the T cells in 96-well fl  at-bottom 
tissue culture plates. Cell proliferation was measured on day 5 by a 16-h 
pulse with [3H]-thymidine (1 μCi/well; BD Biosciences).
FACS analysis. Cell staining was performed using FITC- or PE-conju-
gated mAbs. Labeled antibodies for fl  ow cytometry included anti–CD1a-PE, 
anti–CD1d-PE, anti–HLA-DR-PE, and isotype-matched controls (BD Bio-
sciences), anti–Vβ11-PE and anti–Vα24-FITC (Immunotech), and anti–
HLA-ABC-FITC (W6/32; Abcam). The cells were assessed for fl  uorescence 
intensity using EPICS Elite fl   ow cytometer (Beckman Coulter) or with 
FACS Calibur cytometer (Becton Dickinson).
Expansion of iNKT cells. DCs were treated with 100 ng/ml α-GalCer 
(or with 100 ng/ml GGC) for 24 h to obtain α-GalCer–loaded DCs. 
α-GalCer–pulsed DCs (105 cells) were cocultured with 106 monocyte-
  depleted autologous PBMCs for 5 d in 24-well plates. The expansion 
of iNKT cells was monitored by quantifying Vα24+ Vβ11+ cells by 
FACS analysis.
Human iNKT cell isolation. Monocyte-depleted human PBMCs were 
incubated with anti–Vα24-FITC (Immunotech) for 20 min at 4°C, cells 
were washed, anti–mouse immunoglobulin microbeads were added, and im-
munomagnetic separation was conducted according to the manufacturer’s 
recommendations (VarioMACS; Miltenyi Biotec).
ELISpot for quantifying the activation of iNKT cells. α-GalCer–pulsed 
DCs (104 cells) were cocultured with 103 freshly isolated iNKT cells for 16 h 
in 96-well human INFγ ELISpot plates (R&D Systems). ELISpot plate devel-
opment was performed according to the manufacturer’s recommendations.
Determination of ATRA and retinol concentration. Concentrations of 
ATRA and retinol were measured in cell pellets by our LC-MS method de-
scribed in detail previously (14). In brief, 50–100 mg of cell pellet was diluted 
with a threefold volume of isopropanol, and the extracts were dried in a con-
centrator (Eppendorf 5301) at 45°C. The dried extracts were resuspended 
with 60 μl of methanol, diluted with 40 μl of 60 mM aqueous ammonium 
acetate solution, transferred into the autosampler, and subsequently analyzed 
with an LC-MS system. The LC-MS system consisted of a Waters 2695XE 
separation module, MS-MS detector (Micromass Quattro micro QAA0029; 
Waters), including an APCI ionising option (Ion sabre APCI; Waters).
Microarray analysis. Total RNA was isolated using Trizol Reagent 
  (Invitrogen) and further purifi  ed by using the RNeasy kit (Qiagen). cRNA 
was generated from 5 μg of total RNA by using the SuperScript Choice 
kit (Invitrogen) and the High Yield RNA transcription labeling kit (Enzo 
Diagnostics). Fragmented cRNA was hybridized to Aff  ymetrix  (Santa 
Clara) arrays (HU133 Plus 2.0) according to Aff  ymetrix standard protocols. 
Preliminary data analysis was performed with GCOS software (Aff  ymetrix). 
Further analysis was performed using GeneSpring 7.2 (Agilent). Micro-
array data analyses are described in detail in the supplemental Materials 
and methods.
Real-time quantitative RT-PCR. Total RNA was isolated using 
TRIZOL reagent (Invitrogen). Reverse transcription was performed at 
25°C for 10 min, 42°C for 2 h, and 72°C for 5 min from 100 ng of total 
RNA using Superscript II reverse transcriptase (Invitrogen) and random 
primers (3 μg/μl; Invitrogen). Quantitative PCR was performed using 
real-time PCR (ABI PRISM 7900; Applied Biosystems): 40 cycles at 95°C 
for 12 s and at 60°C for 30 s using Taqman assays. All PCR reactions were 
done in triplicates with one control reaction containing no RT enzyme. The 
comparative Ct method was used to quantify transcripts and normalize to 
36B4 or cyclophilin A. Values are expressed as mean ± SD of the mean. 
Where indicated signifi  cant diff  erences between mean values were evaluated 
using two-tailed, unpaired Student’s t test. In Fig. 2 C, Taqman qPCR low 
density arrays (TLDA; Applied Biosystems) were used to quantify the expres-
sion of RXR and RAR genes in DCs according to the manufacturer’s instruc-
tions. The sequences of the primers and probes are described in the Table S3 
(available at http://www.jem.org/cgi/content/full/jem.20060141/DC1).
Online supplemental material. Microarray data analyses are described in 
detail in the supplemental Materials and methods. Tables S1 and S2 show 
gene expression data obtained by Aff  ymetrix GeneChip analyses on genes 
clustered into cluster 3 and 6, respectively. Table S3 contains the sequences 
of the primers and probes for RT-Q-PCR. Fig. S1 is a comparison of the 
expression of MHC I and II molecules and T cell activation capacity of reti-
noid and PPARγ ligand–activated DCs. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20060141/DC1.
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